Some providers featured on this site may compensate us. This may affect the order and placement of listings but does not influence our editorial ratings or reviews.
Treatments Hub

Verified prices

All verified prices

embody vs altRx vs Medvi: Our Top Three, One Table

Last updated: Sep 1, 2026

Medically reviewed on

How we review

We may earn a commission from links on this page - it never affects our rankings (how we stay objective).

Here’s the short version

Thirty dollars separates these three, and none of them asks for a commitment - so this comparison is really about what each adds on top of the same compounded semaglutide. embody keeps it lean: $49 flat at every dose, free 1-2 day shipping, and a full refund if a provider doesn't approve you. altRx charges $89 and is the only one with a brand-name shelf - Ozempic, Zepbound and Wegovy at published cash prices - plus Buy Now, Pay Later. Medvi's $99 promo is all-inclusive with video visits, a free dietician and care coaching.

embody logo
Licensed US telehealth

Compounded GLP-1 from $49/month; not FDA-approved, free expedited delivery

Visit embody
altRx logo
Licensed US telehealth

Most Comprehensive GLP-1 Medication Access

Visit altRx
Medvi logo
Licensed US telehealth

Summer Sale! up to $100 off

Visit Medvi

embody vs altRx vs Medvi: side by side

Real published prices and terms - the differences that actually decide this matchup.

embodyaltRxMedvi
Semaglutide$49/mo, flat at every dose$89/mo (reg. $199), flat at every dose$99/mo promo (reg. $199), all-inclusive
Tirzepatide$99/mo$149/mo (reg. $299)$166/mo promo (reg. $299)
Billing & commitmentMonthly - no commitment, cancel anytimeMonthly - pause or cancel anytime; Buy Now, Pay LaterMonthly, all-inclusive - no surprise charges; HSA/FSA approved
ShippingFree 1-2 day, tracked & insuredFree nationwide deliveryFree shipping
SupportLicensed doctors, medical director & nursing teamLicensed provider review (physician, PA, or NP)Video visits + free dietician & care coaching
Guarantee / refundFull refund if you're not approved--
StandoutLegitScript-certified; 503A pharmaciesBrand-name shelf: Ozempic $1,149 · Zepbound $1,249 · Wegovy $1,579All-inclusive price; HSA/FSA approved

Our verdict

All three bill monthly with no prepaid term, so the price gap is the honest starting point: $49, $89, $99. Pay the minimum and move fast: embody - cheapest here, quickest shipping, and the refund-if-not-approved policy removes the main risk of trying. Think brand-name Ozempic or Zepbound might be in your future: altRx - it's the only one of the three where that switch happens without changing providers, and BNPL softens the brand prices. Want a person in the loop - video visits, a dietician, someone to call: Medvi. There's no legitimacy gap to worry about: all three run licensed-provider review and dispense through regulated pharmacies.

embody vs altRx vs Medvi: FAQs

Which is cheapest: embody, altRx or Medvi?

For compounded semaglutide: embody at $49/month flat, then altRx at $89/month promotional (regularly $199), then Medvi at $99/month promotional (regularly $199) all-inclusive. For tirzepatide: embody $99, altRx $149 (regularly $299), Medvi $166 promotional (regularly $299). All three bill monthly with no prepaid commitment.

Can I get brand-name Ozempic, Zepbound or Wegovy from any of them?

Only altRx. Alongside its $89/month compounded semaglutide it publishes cash prices for brand-name medication - Ozempic at $1,149, Zepbound at $1,249 and Wegovy at $1,579 per month - with Buy Now, Pay Later available. embody and Medvi focus on compounded GLP-1s.

Do any of these require a long-term commitment?

No - all three bill month to month. embody adds a full refund if a licensed provider doesn't approve you for treatment, altRx lets you pause or cancel anytime, and Medvi's all-inclusive rate is HSA/FSA approved with no surprise charges.

Break it down two at a time

The head-to-head comparisons between these providers.

Medical disclaimer

This page is general information about GLP-1 weight-loss medications such as semaglutide and tirzepatide, published to help you compare services. It is not medical advice, it does not create a doctor-patient relationship, and it is not a substitute for a consultation with a licensed clinician who knows your history. Treatments Hub is not a medical provider, pharmacy or clinic and does not prescribe, sell or dispense medication. Do not start, stop or change any treatment because of something you read here, and do not delay seeking care; in an emergency call 911.

Semaglutide and tirzepatide carry an FDA boxed warning about thyroid C-cell tumours seen in rodents and are not for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2, nor for use in pregnancy. Compounded versions sold by telehealth providers are prepared by state-licensed pharmacies and are not FDA-approved products. Where a review or post on this page mentions weight lost, that is one person's result and is not typical; results vary widely.

Medical and scientific statements on this site are checked against the sources linked on the page by our medical content reviewer, who does not choose providers or set prices. Prices, plans and customer reviews are each provider's published figures and customers' own words on the dates stated. We may earn a commission from provider links. The full medical and advertising disclaimer explains all of this in detail.

Sources & medical references

Treatment facts on this page are grounded in regulatory guidance and peer-reviewed research. Pricing and plan details come from each provider's published information. This content is for information only and is not medical advice - always consult a licensed clinician before starting treatment.

  1. 1.Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial) - New England Journal of Medicine, 2021
  2. 2.Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1 trial) - New England Journal of Medicine, 2022
  3. 3.FDA Approves New Drug Treatment for Chronic Weight Management (semaglutide / Wegovy) - U.S. Food & Drug Administration, 2021
  4. 4.FDA Approves New Medication for Chronic Weight Management (tirzepatide / Zepbound) - U.S. Food & Drug Administration, 2023
  5. 5.FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss - U.S. Food & Drug Administration
  6. 6.Human Drug Compounding (503A pharmacy standards) - U.S. Food & Drug Administration
  7. 7.Semaglutide Injection - drug information - MedlinePlus, U.S. National Library of Medicine (NIH)